Page 87 - 《中国药房》2025年14期

·药物经济学·

卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价
Δ

#
＊
杨颂恬 ，严 波（重庆医科大学公共卫生学院，重庆 400016）
中图分类号 R956 文献标志码 A 文章编号 1001-0408（2025）14-1765-05
DOI 10.6039/j.issn.1001-0408.2025.14.13

摘 要 目的 对卡瑞利珠单抗联合化疗用于我国宫颈癌患者的经济性进行评价。方法 从中国卫生体系角度出发，基于卡瑞利
珠单抗联合化疗治疗宫颈癌的文献资料构建Markov模型，其中不良反应发生情况通过Meta分析获得。设置研究时限为10年，循
环周期为3周。成本包括药品成本、不良反应治疗成本等直接成本，效用值参考现有研究，转移概率基于文献数据计算，贴现率为
5%，意愿支付（WTP）阈值采用3倍我国2024年人均国内生产总值（GDP）即287 247元/质量调整生命年（QALY），比较卡瑞利珠单
抗联合或不联合化疗的经济性，并通过单因素敏感性分析和蒙特卡罗模拟评估参数波动对结果的影响。结果 与单用卡瑞利珠单
抗方案比较，卡瑞利珠单抗联合化疗方案的增量成本-效果比为181 507.58元/QALY，小于本研究设定的WTP阈值。单因素分析
结果显示，两组无进展生存状态到死亡的转移概率对结果的影响较大；概率敏感性分析结果表明，以3倍我国2024年人均GDP为
WTP阈值时，卡瑞利珠单抗联合化疗方案具有经济性的概率为 91.8%。结论 从中国卫生体系角度出发，与单用卡瑞利珠单抗方
案比较，当以3倍我国2024年人均GDP为WTP阈值时，卡瑞利珠单抗联合化疗用于我国宫颈癌患者具有经济性。
关键词 卡瑞利珠单抗；宫颈癌；药物经济学评价

Pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the treatment of cervical
cancer in China
YANG Songtian，YAN Bo（School of Public Health， Chongqing Medical University， Chongqing 400016， China）

ABSTRACT OBJECTIVE To perform a pharmacoeconomic evaluation of camrelizumab combined with chemotherapy in the
treatment of cervical cancer in China. METHODS From the perspective of China’s healthcare system， a Markov model was
constructed based on literature data regarding the treatment of cervical cancer with camrelizumab combined with chemotherapy，
where the incidence of adverse reactions was obtained through a meta-analysis. The model was run over a 10-year time horizon with
a 3-week cycle length. Costs included direct costs （e.g. drug cost， adverse event treatment cost）. Utility values were derived from
existing studies， and transition probabilities were calculated using literature data， with a discount rate of 5%； the willingness-to-pay
（WTP） threshold was set at 3 times China’s 2024 per capita gross domestic product （GDP）， i.e. 287 247 yuan/quality-adjusted life
year（QALY）. Cost-effectiveness was compared between camrelizumab combined with chemotherapy and monotherapy. One-way
sensitivity analysis and Monte Carlo simulation were used to evaluate the impact of parameter variations on results. RESULTS
Compared with camrelizumab monotherapy， the incremental cost-effectiveness ratio （ICER） of camrelizumab combined with
chemotherapy was 181 507.58 yuan/QALY， below the predefined WTP threshold. One-way sensitivity analysis showed that the
outcomes were largely affected by the progression-free survival-to-death transition probabilities in both groups. Probabilistic
sensitivity analysis indicated a 91.8% probability of camrelizumab combined with chemotherapy being cost-effective at a WTP
threshold of 3 times China’s 2024 per capita GDP. CONCLUSIONS From China’s healthcare system perspective， camrelizumab
combined with chemotherapy is cost-effective for cervical cancer in China， compared with monotherapy， when using 3 times
China’s 2024 per capita GDP as the WTP threshold.
KEYWORDS camrelizumab； cervical cancer； pharmacoeconomic evaluation

Δ 基金项目 重庆市自然科学基金面上项目（No.cstc2021jcyj-
msxmX0259） 宫颈癌的发病率在全球女性常见肿瘤中居第 4
＊第一作者 硕士研究生。研究方向：药物经济学。E-mail： [1]
位 。据统计，2022 年我国宫颈癌新发病例 15.07 万例，
953656285@qq.com
[2]
死亡病例5.57万例 。虽然我国在宫颈癌筛查及疫苗接
# 通信作者 研究员，硕士生导师，硕士。研究方向：药事管理、药
物经济学。E-mail：yanbo@cqmu.edu.cn 种方面已取得重大进步，但筛查和接种的覆盖率仍然有

中国药房 2025年第36卷第14期 China Pharmacy 2025 Vol. 36 No. 14 · 1765 ·